Middle East respiratory syndrome coronavirus vaccine - Vaccitech

Drug Profile

Middle East respiratory syndrome coronavirus vaccine - Vaccitech

Alternative Names: ChAdOx1 MERS vaccine; MERS vaccine - Vaccitech; MERS-CoV vaccine – Vaccitech

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Oxford
  • Developer University of Oxford; Vaccitech
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Middle East respiratory syndrome coronavirus

Most Recent Events

  • 14 Mar 2018 Phase-I clinical trials in Middle East respiratory syndrome coronavirus (Prevention) in United Kingdom (IM) (NCT03399578)
  • 25 Jan 2018 University of Oxford plans a phase I trial for Middle East respiratory syndrome coronavirus (Prevention) in United Kingdom in January 2018 (NCT03399578)
  • 15 Jan 2018 Vaccitech plans a phase I trial for Middle East respiratory syndrome coronavirus (Prevention) in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top